Firm leaders aren’t invulnerable. RIAs should have backup plans in place to prevent chaos in the event of sudden bad news.

In the preceding three months, 4 analysts have released ratings for Arcellx ACLX -0.01% Get Free Report , presenting a wide array of perspectives from bullish to bearish. The table below summarizes ...

Lung POCUS has become an essential tool in hospital medicine, offering rapid bedside assessment of respiratorypathologies, ...

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., Jul ...

Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic ...

Sequentify is pleased to announce the appointment of Dr. Ravi Majeti, a world-renowned expert in hematologic malignancies, as ...

Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients ...

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update ...

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Find out how leukemia cells affect the treatment of pediatric patients with B-cell acute lymphoblastic leukemia and acute ...

New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company ...